Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584469 | 0.80 | IRAK4 (0.43) | PDE4BIRAK4JAK3MEN1NPC1 | |
| SCHEMBL212827 | 0.76 | PDE4B (0.39) | PDE4BIRAK4JAK3NPC1RAB9A | |
| SCHEMBL5790483 | 0.76 | HSD17B10 (0.44) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL210666 | 0.75 | HDAC1 (0.62) | NPC1RAB9AHDAC1HDAC3 | |
| SCHEMBL11936086 | 0.73 | KDR (0.48) | IRAK4JAK3KDRROCK1MEN1 | |
| SCHEMBL24904477 | 0.73 | KDR (0.62) | KDRROCK1MEN1NPC1RAB9A | |
| SCHEMBL28086793 | 0.73 | NPC1 (0.46) | IRAK4JAK3KDRROCK1MEN1 | |
| SCHEMBL212553 | 0.72 | NPC1 (0.61) | KDRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL2696488 | 0.71 | IRAK4 (0.73) | IRAK4JAK3 | |
| SCHEMBL5341775 | 0.70 | BCAT2 (0.49) | PDE4BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | PDE4B 2728/4885IRAK4 3790/4885JAK3 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.